Cargando…

Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective

INTRODUCTION: Hyperkalemia is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD). Patiromer (Veltassa(®)) is an oral potassium binder indicated for the treatment of hyperkalemia in adults. We evaluated the impact of patiromer on the Swiss healthcare resou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Barbara, Serra, Andreas, Telser, Harry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122858/ https://www.ncbi.nlm.nih.gov/pubmed/35416597 http://dx.doi.org/10.1007/s12325-022-02123-3

Ejemplares similares

Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors
por: Weinstein, Jordan, et al.
Publicado: (2021)

Is It Time to Rethink the Age-Old Practice of Permissive Hyperkalemia in Renin-Angiotensin-Aldosterone Inhibition?
por: Ambruso, Sophia L.
Publicado: (2021)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
por: Kohsaka, Shun, et al.
Publicado: (2022)

Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes
por: An, Jaejin, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Rosano, Giuseppe MC, et al.
Publicado: (2019)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study
por: Jun, Min, et al.
Publicado: (2019)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Independent regulation of renin–angiotensin–aldosterone system in the kidney
por: Nishiyama, Akira, et al.
Publicado: (2018)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Real‐World Associations Between Renin‐Angiotensin‐Aldosterone System Inhibition Therapy, Hyperkalemia, and Outcomes: A Clinical and Scientific Call to Action
por: Chapman, Arlene, et al.
Publicado: (2019)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and kidney interactions in heart failure
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study
por: Dwyer, Jamie P., et al.
Publicado: (2023)

Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study
por: Agiro, Abiy, et al.
Publicado: (2023)

The Yin and Yang of the Renin–Angiotensin–Aldosterone System in Acute Kidney Injury
por: Legrand, Matthieu, et al.
Publicado: (2021)

Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome
por: Stiefel, P., et al.
Publicado: (2011)

The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling
por: Pacurari, Maricica, et al.
Publicado: (2014)

Management of proteinuria: blockade of the renin–angiotensin–aldosterone system
por: Athavale, Akshay, et al.
Publicado: (2020)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Interactions of the DASH Diet with the Renin-Angiotensin-Aldosterone System
por: Maris, Stephen A, et al.
Publicado: (2019)

Erratum for The renin‐angiotensin‐aldosterone system and its suppression
Publicado: (2019)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

Renin-angiotensin-aldosterone system and COVID-19 infection
por: Alexandre, Joachim, et al.
Publicado: (2020)

The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
por: Coto, Eliecer, et al.
Publicado: (2021)

Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system
por: Mandal, Amit.K.J., et al.
Publicado: (2021)

The Retinal Renin-Angiotensin-Aldosterone System: Implications for Glaucoma
por: Hirooka, Kazuyuki, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial
por: Bakris, George L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ktdd2kqvdf2pnqm8kioma3vpd